AMANTA vs NEPHROPLUS: Stock Comparison

Amanta Healthcare Limited vs Nephrocare Health Services Ltd

Live data: 16 June 2026, 4:08 PM IST • Source: NSE and company filings

Nephrocare Health Services Ltd is the larger company by market capitalisation. Amanta Healthcare Limited shows a lower P/E and faster revenue growth, while Nephrocare Health Services Ltd shows a higher ROE, lower leverage and a higher ROCE. These are relative readings on individual metrics — weigh valuation against growth, margins, leverage and capital efficiency rather than treating any single number as decisive.

Side-by-side comparison of Amanta Healthcare Limited and Nephrocare Health Services Ltd on live price, valuation, growth, profitability, leverage and quarterly shareholding. Highlighted values mark the more favourable of the two on that metric's usual reading; a single metric is never the full story.

On standard readings, AMANTA is more favourable on 3 of 11 scored metrics and NEPHROPLUS on 7These counts are context-free and are not an overall rating.

Key Differences

Market Cap
NEPHROPLUS is the larger company
₹6,783 Cr vs ₹641 Cr
P/E Ratio
AMANTA has a lower P/E
42.56x vs 88.07x
P/B Ratio
AMANTA has a lower P/B
2.87x vs 6.06x
EPS
NEPHROPLUS has higher earnings per share
₹7.66 vs ₹4.33
Revenue Growth (TTM YoY)
AMANTA has faster revenue growth
6.8% vs 0%
EPS Growth (TTM YoY)
NEPHROPLUS has faster EPS growth
0% vs -23.4%
ROE
NEPHROPLUS has a higher ROE
9.06% vs 6.75%
ROCE
NEPHROPLUS has a higher ROCE
15.5% vs 0%

Each difference is a single, relative reading — StockeZee does not name an overall winner.

Profile

MetricAMANTANEPHROPLUS
SectorHealthcare
IndustryPharmaceuticals

Price

MetricAMANTANEPHROPLUS
Live Price₹150.27₹673.1
Day Change-4.37%-0.71%
Volume3.82 L87,056
52-Week High₹164₹769.75
52-Week Low₹92₹446
Distance from 52W High-8.37%-12.56%

Valuation

MetricAMANTANEPHROPLUS
Market Cap₹641 Cr₹6,783 Cr
P/E Ratio42.56x88.07x
P/B Ratio2.87x6.06x
EPS₹4.33₹7.66
Book Value₹64.09₹111
Dividend Yield0%0%

Growth

MetricAMANTANEPHROPLUS
Revenue Growth (TTM YoY)6.8%0%
EPS Growth (TTM YoY)-23.4%0%
Qtr Sales Growth21.2%
Qtr Profit Growth22.1%

Profitability & Leverage

MetricAMANTANEPHROPLUS
ROE6.75%9.06%
ROCE0%15.5%
Net Margin5.17%7.69%
Operating Margin14.55%22.4%
Debt to Equity1.06x0.07x

Shareholding

As of Mar 2026 • change vs previous quarter
MetricAMANTANEPHROPLUS
Promoter Holding26.81% 0.16 pp21.07%
FII Holding0.85% 0.25 pp8.78% 1.16 pp
DII Holding12.88% 1.64 pp9.05% 0.4 pp
Public Holding22.56% 1.54 pp18.32% 0.76 pp

How to Read This Comparison

Valuation ratios (P/E, P/B) use the latest consolidated figures where available; growth numbers compare against the same period last year; shareholding percentages come from the most recent quarterly filings, with the change shown against the prior quarter. A "more favourable" highlight is relative between these two companies only — it is not a rating, a recommendation, or a comparison against the wider sector. Rows with no reported data for either company are hidden rather than shown empty.

Deep-dive each company on its stock page for quarterly results, technicals, filings and the full peer set: Amanta Healthcare Limited and Nephrocare Health Services Ltd.

Data source: NSE and company filings via StockeZee. This comparison is informational — it is not investment advice, and StockeZee is not a SEBI-registered investment adviser.